HUMA Humacyte, Inc
Price Chart
Executive Summary
Humacyte priced a $50M underwritten public offering of 47.6M shares at $1.05 per share, representing a roughly 20% discount to the last close and massive dilution (estimated ~53% of pre-offerring shares). Proceeds fund Symvess commercialization, a BLA supplement for hemodialysis, and pipeline development. This is a clear capital raise from a cash-burning commercial-stage biotech with meaningful dilution.
Key Financial Metrics
Actionable Insight
Massive dilution from a cash-hungry commercial-stage biotech. Monitor post-close cash runway and any updates on Symvess adoption and hemodialysis BLA timing. The 30-day overs allotment option adds further overhang. Likely near-term weakness given the magnitude of new shares.
Key Facts
- 47,619,048 shares priced at $1.05 per share for $50M gross proceeds
- Underwriters have 30-day option for another 7,142,857 shares (up to ~$7.5M additional)
- Offering represents ~53% dilution vs pre-offering shares (pre-offering shares ~90M; pro forma ~137.6M)
- Proceeds fund Symvess commercialization, BLA supplement for hemodialysis, and pipeline/working capital
- Closing expected June 12, 2026; Barclays, BTIG, and Titan Partners are joint book-runners
Financial Impact
$50M gross proceeds; dilution of ~53% on pre-offering share count; $1.05 offering price is last price not disclosed but likely at a discount
Risk Factors
- Dilution of ~53% will pressure EPS and book value; sentiment likely negative
- Commercial adoption of Symvess is still early; capital may get consumed quickly without commensurate revenue
- Hemodialysis BLA submission and approval are uncertain; pipeline spending may not deliver catalysts soon
- Underwriter option for 7.1M additional shares could add 8% more dilution
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310172 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Institutional Cluster
| $1.07 awaiting T+5 | awaiting T+5 | — | $1.05 (−0.94%) |
|
Jun 11, 2026
3d ago
|
8-K
| $1.07 awaiting T+5 | awaiting T+5 | — | $1.05 (+1.40%) |
|
Jun 11, 2026
4d ago
|
Press Release
| $1.16 awaiting T+5 | awaiting T+5 | — | $1.05 (+9.05%) |
|
Jun 11, 2026
4d ago
|
Press Release
| $1.16 awaiting T+5 | awaiting T+5 | — | $1.05 (+9.05%) |
|
Jun 10, 2026
4d ago
|
Press Release
| $1.35 awaiting T+5 | awaiting T+5 | — | $1.05 (−21.85%) |
|
May 20, 2026
25d ago
|
Insider Cluster
| $1.02 $1.28 | ▲ +25.49% | ▲ +23.89% | $1.05 (+3.43%) |
|
May 13, 2026
4w ago
|
Press Release
| $1.13 $0.8250 | ▼ −26.99% | ▼ −25.83% | $1.05 (−6.64%) |
|
May 8, 2026
5w ago
|
Press Release
| $1.06 $1.00 | ▼ −5.66% | ▼ −7.12% | $1.05 (−0.47%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $0.6590 $0.8480 | ▲ +28.68% | ▲ +27.60% | $1.05 (+60.09%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $0.8500 $0.5750 | ▼ −32.35% | ▼ −28.79% | $1.05 (+24.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access